In chronic lymphocytic leukemia (CLL), autonomous autoreactive BCR signaling contributes to tumor cell survival5, and established targeted therapy concepts focus on inhibiting oncogenic kinases in the BCR pathway6–8, resulting in signal deprivation and thereby cell death9,10. The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.